For immediate release |
6 March 2009 |
Futura Medical plc
('Futura' or 'the Company')
Notification of Interest
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, was notified on 6 March 2009 that, following the purchase of shares in the Company on the same day, P Mahon holds 2,083,302 ordinary shares in Futura, representing 3.3% of the issued share capital of the Company.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive |
Tel: +44 (0) 1483 685 670 |
|
|
mail to: james.barder@futuramedical.co.uk |
|
|
|
Canaccord Adams |
|
Ryan Gaffney / Adria Da Breo Richards |
Tel: +44 (0) 20 7050 6500 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court / Rebecca Skye Dietrich / Stasa Filiplic |
Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.